Gossamer Bio will reduce authorized common shares from 4,000,000,000 to 50,000,000 and total authorized Capital Stock from 4,070,000,000 to 120,000,000. The change accompanies a Reverse Stock Split intended to help restore Nasdaq minimum bid-price compliance, with split-adjusted trading expected on September 11, 2026.

Key Highlights

  • Split-adjusted trading is expected to begin on September 11, 2026, under the existing GOSS symbol.
  • Stockholders’ percentage ownership and voting power will remain unchanged apart from minor fractional-share effects.
  • Authorized common shares will be reduced from 4,000,000,000 to 50,000,000.
  • The changes are expected to take effect on September 10, 2026, to help regain compliance with Nasdaq’s minimum bid-price requirement.

Gossamer Bio, Inc. (NASDAQ: GOSS) plans to reduce its authorized common shares from 4,000,000,000 to 50,000,000 as part of a reverse stock split and related capital-stock reduction. The measure is intended to help the biotechnology company regain compliance with Nasdaq’s minimum bid-price requirement, with the changes expected to take effect on September 10, 2026.

Authorized Shares Set For Sharp Reduction

The total number of authorized capital-stock shares will fall from 4,070,000,000 to 120,000,000. Gossamer Bio will continue using the GOSS trading symbol. The common stock’s Par Value will remain $0.0001 per share.

Ownership Percentages Expected To Remain Unchanged

Each stockholder’s percentage ownership and proportional voting power are expected to remain unchanged immediately after the reverse stock split, except for minor effects from fractional-share treatment. Computershare Trust Company, N.A. is serving as transfer agent and exchange agent. Registered holders and investors holding shares through brokers, banks or other nominees are not required to take action, although intermediaries may use their own processing procedures.